Figure 4From: Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation statusThe antitumor effect of dovitinib and/or oxaliplatin on the xenograft of colon cancer. Treatment with dovitinib and oxaliplatin significantly decrease the growth of HT29 colon cancer xenografts in athymic mice. In these experiments, mice were treated with 60 mg/kg dovitinib (oral/2 days) and/ or 6.7 mg/kg oxaliplatin (i.v., once/week). Matched control mice bearing xenografts received an equal volume of saline on the same treatment schedule. Significance was determined using a two-way ANOVA. (Ai) Tumor volume changes after administration of drugs. (Aii) Bar diagram (Mean ± SEM) showing the tumor volume on day 28 after the treatment, n = 10; *P < 0.05 and #p < 0.01. (B) Tumor growth delay in various treatment groups calculated from a Log-linear growth plot. (C) Representative panel of immunohistochemical analysis of (i) Ki-67 and (ii) CD-31 (cluster of differentiation molecule also known as PECAM-1) in tumors extracted from mice with/without treatment with dovitinib and/or oxaliplatin. Magnification (10×) with inset at (40×). (iii) H & E staining of corresponding sections from untreated and treated tumors. (D) Bar diagram (Mean ± SEM) showing the quantitation of average number of Ki-67 positive cells and CD-31 positive vessels as percentage of saline treated control, n = 10; * P < 0.05. Combination of dovitinib and oxaliplatin inhibits the tumor growth by inhibition of cell proliferation and angiogenesis.Back to article page